GRTX נכסי החברה Galera Therapeutics

Galera Therapeutics (GRTX) is attracting radiation therapy specialists by offering them participation in the development of methods to reduce treatment side effects. The company creates patent-protected small molecules, where success depends on FDA verdicts. Currently, the business is winding down due to regulatory failures, focusing instead on the sale of rights. Total assets amount to 0.00, as reflected by the price action on the GURU.Markets platform.

For Galera Therapeutics (GRTX), which develops patient protection agents for radiotherapy, total assets define the scale of the resource base available for conducting clinical trials. This value of controlled resources, calculated inversely via return on assets (ROA), combines equity and liabilities, allowing investors to assess the balance between the tangible strengthening of the business and the risk of excessive debt load during the scaling of the therapy.